
0:00
7:00
It's a thin week for acromegaly-specific research — no top-tier-journal hits, so we're covering the best next-tier evidence on GH-axis physiology, octreotide drug delivery, and pituitary imaging AI — while rare disease industry news delivers a sharp one-two: Ionis just won the first-ever approval for Alexander disease, days after Ultragenyx's marquee Angelman syndrome drug flopped in Phase 3.
More episodes from "Acromegaly Update"



Don't miss an episode of “Acromegaly Update” and subscribe to it in the GetPodcast app.








